Why InterMune, Inc. Shares Rallied This Morning

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of InterMune, Inc.  (NASDAQ: ITMN  ) popped about 4% in premarket trading Tuesday after Goldman Sachs upgraded the biotechnology company from neutral to buy.

So what: Along with the upgrade, analyst Terence Flynn boosted his price target to $45 (from $40), representing about 34% worth of upside to yesterday's close. So while contrarians might be turned off by the stock's massive year-to-date surge, Flynn's call suggests that InterMune's growth potential gives it plenty of room to run.

Now what: Goldman raised its 2015 per-share view for InterMune from ($0.32) to ($0.04) and its 2016 outlook from $1.02 to $1.56. "In late February, ITMN reported better-than- expected top-line Ph3 data for key drug, Esbriet for IPF (an orphan lung indication), which in our view de-risks the US opportunity (we model $1.3bn US peak)," said Flynn. "Our conversations with investors suggest outstanding concerns regarding Esbriet's efficacy (treatment effect size) as well as the competitive landscape." Of course, with the stock already up a whopping 135% in 2014, I'd wait for a much wider margin of safety before jumping in. 

More great ways to grow
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2871905, ~/Articles/ArticleHandler.aspx, 10/31/2014 9:47:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,291.97 96.55 0.56%
S&P 500 2,012.79 18.14 0.91%
NASD 4,640.41 74.27 1.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ITMN $0.00 Down +0.00 +0.00%
InterMune CAPS Rating: **

Advertisement